FDA ODAC Recommends Pembrolizumab for the Treatment of Certain Patients with High-Risk, Non-Muscle Invasive Bladder Cancer

ODAC FDA voted in favor of recommending KEYTRUDA Merck’s anti-PD-1 therapy pembrolizumab for the treatment of certain patients with high-risk non-muscle invasive bladder cancer (NMIBC) keynote 057, BCG unresponsive bladder cancer

Read the full article here

Related Articles